Trial Profile
CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs GPC3-CAR-T (Primary) ; GPC3-CAR-T (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- 26 Feb 2023 Planned End Date changed from 1 Aug 2024 to 1 Aug 2029.
- 26 Feb 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2025.
- 28 Nov 2020 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.